Trial Profile

A Phase I/II trial of GLIX-1 as a monotherapy or in combination with PARP inhibitors to evaluate a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy in patients with recurrent Glioblastoma (GBM) and solid tumours

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2025 Accoridng to a BioLineRx media release, phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026.
07 Nov 2025 New trial record
29 Sep 2025 According to BioLineRx media release, the data from the Phase 1 part of the trial is anticipated in H1 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com